TroVax® vaccine therapy for renal cell carcinoma

Immunotherapy

Volumn 4, Issue 1, 2012, Pages 27-42

  Zhang, Rui Tao ^a   Bines, Steven D ^a   Ruby, Carl ^a   Kaufman, Howard L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5T4; modified vaccinia virus Ankara; renal cell carcinoma; vaccine

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BIOLOGICAL MARKER; DENILEUKIN DIFTITOX; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; IRINOTECAN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; OXALIPLATIN; PAZOPANIB; PHENACETIN; PLACEBO; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR ANTIGEN;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BLOOD CLOTTING DISORDER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG MEGADOSE; DRUG SCREENING; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; MELANOMA; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEINURIA; RADICAL RESECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS; MODELS, IMMUNOLOGICAL; TREATMENT OUTCOME;

EID: 83655193361     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.160     Document Type: Article

References (88)

1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA, USA. American Cancer Society (2011).
2. Young R. Metastatic renal cell carcinoma: what causes occasional dramatic regressions? N. Engl. J. Med. 338, 1305-1306 (1998). (Pubitemid 28216587)
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
4. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ. Sex differences in renal cell cancer presentation and survival: An analysis of the National Cancer Database, 1993-2004. J. Urol. 179(5), 1709-1713 (2008).
5. Kidney. In: AJCC Cancer Staging Manual. Edge SB, Byrd DR, Compton CC (Eds). Springer, NY, USA, 479 (2009).
6. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J. Clin. Oncol. 23(12), 2763-2771 (2005). (Pubitemid 46179466)
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999). (Pubitemid 29368255)
8. Suppiah R, Shaheen PE, Elson P et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107(8), 1793-1800 (2006). (Pubitemid 44582948)
9. Flaherty KT, Fuchs CS, Colditz GA et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 16(9), 1099-1106 (2005). (Pubitemid 41356008)
10. Lonser RR, Glenn GM, Walther M et al. Von Hippel-Lindau disease. Lancet 361(9374), 2059-2067 (2003). (Pubitemid 36695052)
11. Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occ. Med. 52(3), 157-164 (2002). (Pubitemid 34649665)
12. Cancer Treatment and Research: Kidney Cancer. Figlin RA (Ed.). Volume 116 (2003).
13. Prasad SR, Humphrey PA, Catena JR et al. Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation. Radiographics 26, 1795-1806 (2006).
14. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27(5), 612-624 (2003). (Pubitemid 36514472)
15. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non clear-cell histology. J. Clin. Oncol. 20, 2376-2381 (2002). (Pubitemid 34441667)
16. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: Analysis of the National Cancer Center Database. Cancer 113(1), 78-83 (2008). (Pubitemid 351976389)
17. Resnick MI, Older RA. Diagnosis of Genitourinary Disease (2nd Edition). Thieme Medical Publishers, NY, USA, 168-170 (1997).
18. Motzer RJ, Russo P. System therapy for renal cell carcinoma. J. Urol. 163(2), 408-417 (2000). (Pubitemid 30060482)
19. Lerner SE, Hawkins CA, Blute ML et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J. Urol. 155(6), 1868-1873 (1996). (Pubitemid 26144074)
20. Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol. Clin. North Am. 30(3), 601-609 (2003). (Pubitemid 37059565)
21. Clement JM, McDermott DF. The high-dose aldesleukin (IL 2) "select" trial: A trial to prospectively validate predictive models of response to high-dose IL 2 treatment in patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7(2), E7-E9 (2009).
22. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin 2: Identification of the antigens mediating response. Ann. Surg. 228(3), 307-319 (1998). (Pubitemid 30191694)
23. Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/ EORTC GU 30012): An open-label randomised trial. Lancet 375(9715), 641-648 (2010).
24. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
25. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007). (Pubitemid 46089673)
26. Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 5021 (2009).
27. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa 2a for treatment of metastatic renal cell carcinoma: A randomised, double blind Phase III trial. Lancet 370, 2103-2111 (2007). (Pubitemid 350296300)
28. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). (Pubitemid 46849157)
29. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
30. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893).
31. Burnet FM. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970).
32. Kim R, Emi M, Tanabe K. Cancer immunoediting: From immune surveillance to immune escape. Immunology 121(1), 1-14 (2007). (Pubitemid 46537674)
33. Chang CC, Ogino T, Mullins DW et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2 microglobulin loss-of-function in melanoma cells. J. Biol. Chem. 281, 18763-18773 (2006). (Pubitemid 44035537)
34. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
35. Sharma S, Stolina M, Lin Y et al. T cell-derived IL 10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163, 5020-5028 (1999). (Pubitemid 29501270)
36. Elkord E, Dangoor A, Burt DJ et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA 5T4). Cancer Immunol. Immunother. 58, 1567-1567 (2009).
37. Jager E, Jager D, Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 106, 817-820 (2003). (Pubitemid 37071658)
38. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit. Rev. Immunol. 18(4), 275-303 (1998). (Pubitemid 28364148)
39. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10(4), 248-256 (2010).
40. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4, 627-630 (1998). (Pubitemid 28237366)
41. Shah S, Divekar AA, Hilchey SP et al. Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117, 574-586 (2005). (Pubitemid 41504545)
42. 8+T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184(7), 4006-4016 (2010).
43. 25+ suppressor T cells: More questions than answers. Nat. Rev. Immunol. 2, 389-400 (2002). (Pubitemid 37328746)
44. Antony PA, Paulos CM, Ahmadzadeh M et al. Interleukin 2-dependent mechanisms of tolerance and immunity in vivo. J. Immunol. 176, 3301-3305 (2006).
45. Rasku MA, Clem AL, Telang S et al. Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 6, 12 (2008).
46. 25+ regulatory T cells in patients treated with high-dose interleukin 2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169-1177 (2006). (Pubitemid 46638815)
47. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
48. 8+T cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 63, 4481-4489 (2003). (Pubitemid 36951020)
49. Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int. J. Immunol. 20, 1057-1066 (2008).
50. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61(1), 89-95 (1990).
51. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer 57, 239-246 (1998).
52. Neumann E, Engelsberg A, Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE 1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T cell-based immunotherapies? Cancer Res. 58(18), 4090-4095 (1998). (Pubitemid 28440562)
53. Nicholau T, Ebert L, Davis ID et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY ESO 1. Immunol. Cell Biol. 84, 303-317 (2006).
54. Woods AM, Wang WW, Shaw DM et al. Characterization of the murine 5T4 oncofoetal antigen: A target for immunotherapy in cancer. Biochem. J. 366, 353-365 (2002). (Pubitemid 34971836)
55. Carsberg CJ, Myers KA, Evans GS, Allen TD, Stern PL. Metastasis- associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane. J. Cell. Sci. 108, 2905-2916 (1995).
56. Naganuma H, Kono K, Mori Y et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res. 22, 1033-1038 (2002). (Pubitemid 34836147)
57. Smyth LJC, Elkord E, Taher TE et al. CD8 T cell recognition of human 5T4 oncofetal antigen. Int. J. Cancer 119(7), 1638-1647 (2006). (Pubitemid 44258770)
58. 25+ T cells. Cancer Immunol. Imunother. 57, 833-847 (2008).
59. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schäfer H, Holzner A. MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain. Dtsch Med. Wochenschr. 99(47), 2386-2392 (1974).
60. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin. Oncol. 32, 549-555 (2005). (Pubitemid 41772682)
61. Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors. Curr. Opin. Mol. Ther. 7, 317-325 (2005). (Pubitemid 41103051)
62. Mulryan K. Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 1, 1129-1137 (2002).
63. 4+ T cell dependent and antibody mediated. Cancer Immunol. Immunother. 55(9), 1081-1090 (2006). (Pubitemid 43800723)
64. Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class I-restricted T cell epitope in the tumour-associated antigen, 5T4. Immunology 118(1), 50-57 (2006).
65. Harrop R, Connolly N, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A Phase I/II trial. Clin. Cancer Res. 12, 3416-3424 (2006).
66. Elkord E, Dangoor A, Drury NL et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J. Immunother. 31, 820-829 (2008).
67. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 13, 4487-4494 (2007). (Pubitemid 47219718)
68. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5 fluorouracil, leucovorin, and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57, 977-986 (2008).
69. Ramakrishnan R, Antonia S, Gabrilovich DI. Combined modality immunotherapy and chemotherapy: A new perspective. Cancer Immunol. Immunother. 57, 1523-1529 (2008).
70. Amato RJ, Drury N, Naylor S et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): A Phase 2 trial. J. Immunother. 31, 577-585 (2008).
71. Amato RJ, Shingler W, Naylor S et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A Phase II trial. Clin. Cancer Res. 14, 7504-7510 (2008).
72. Kaufman HL, Taback B, Sherman W et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl. Med. 7, 2 (2009).
73. Amato RJ, Shingler W, Goonewardena M et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFNalpha): A Phase 2 trial. J. Immunother. 32, 765-772 (2009).
74. Hawkins RE, McDermott C, Shablak A et al. Vaccination of patients with metastatic renal cell cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J. Immunother. 32, 424-429 (2009).
75. Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled Phase III study. Clin. Cancer Res. 16(22), 5539-5547 (2010).
76. Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. TroVax: A recombinant modified vaccinia ankara virus encoding 5T4: lessons learned and future development. Hum. Vacc. 6(10), 1-8 (2011).
77. Harrop R, Shingler WH, McDonald M et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol. Imunother. 60(6), 829-837 (2011).
78. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
79. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
80. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388-1397 (2010).
81. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc. Natl Acad. Sci. USA 107(4), 1524-1528 (2010).
82. Francisco LM, Sage PT, Sharpe AH. The PD 1 pathway in tolerance and autoimmunity. Immunol. Rev. 236(1), 219-242 (2010).
83. Curran MA, Montalvo W, Yagita H, Allison JP. PD 1 and CTLA 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275-4280 (2010).
84. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type 1 immune suppression and decreases T regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
85. 8+T cells. Int. J. Cancer 126(7), 1666-1674 (2010).
86. Huang B, Zhao J, Li H et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009-5014 (2005). (Pubitemid 40827306)
87. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 22, 3696-3705 (2008).
88. Grange C, Tapparo M, Collino F et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71, 5346-5356 (2011).